Clinical trials
Harnessing the Power of AI to Speed Drug Discovery and Development
By Newsroom editorial staff
Lundbeck and a data-driven drug design company are collaborating to utilize AI to identify clinical candidates for brain disorder therapies.
Lundbeck Brings Potential New Biologic Treatment of Parkinson’s Disease into Clinical Development
H. Lundbeck A/S (Lundbeck) begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the first participant in a Phase I study with the compound Lu AF82422.
The Alzheimer's Research Revolution
By Gary Tong, MD, PhD
There’s a revolution underway in the Alzheimer’s research world. At the heart is a change in the way researchers and regulators define and stage the disease, and it might just lead to the breakthrough Alzheimer’s researchers, patients and families have been waiting for.
Lundbeck Starts Clinical Development of Potential New Treatment of Parkinson's Disease
H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a potential new treatment of Parkinson’s disease. The compound – Lu AF28996– is invented by Lundbeck and will now be studied in healthy volunteers as first part of its clinical development.